Dupixent, known generically as dupilumab, is currently protected by numerous patents in the United States, meaning its patent expiration will be a complex and staggered process. The drug's primary patent protection is anticipated to expire around 2034. However, additional patents and data exclusivity could extend market protection beyond this date [1].
When will U.S. market exclusivity for Dupixent end?
The initial market exclusivity for Dupixent in the U.S. is expected to conclude around 2034, based on its primary patent [1]. This date could be influenced by the outcome of ongoing patent challenges and the expiration of secondary patents that cover various aspects of the drug, such as its formulation or method of use.
What happens if a patent is challenged?
Patent challenges, often brought by generic manufacturers seeking to enter the market, can lead to earlier expiration dates if successful [2]. These legal battles can be lengthy and complex, and their outcomes are not always predictable. If a patent is invalidated or its claims are found not to be infringed, generic versions of Dupixent could become available sooner than anticipated [3].
Can biosimilars be approved before patent expiration?
The pathway for biosimilars to enter the market before patent expiration is generally limited. Biosimilar applications are typically reviewed by regulatory agencies after key patents expire or are found to be invalid [2][3]. For Dupixent, the timeline for biosimilar entry will depend on the resolution of patent disputes and the strength of the remaining patent protections.
Who makes Dupixent?
Dupixent is developed and marketed by Regeneron Pharmaceuticals and Sanofi [4].
How does Dupixent work?
Dupixent is a monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. These cytokines are key drivers of inflammation in type 2 inflammatory diseases [5]. By blocking these pathways, Dupixent reduces inflammation and helps to alleviate symptoms associated with conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps [5].
What conditions is Dupixent approved for?
In the U.S., Dupixent is approved for the treatment of moderate-to-severe atopic dermatitis in patients 6 months of age and older whose disease is not adequately controlled by topical therapies. It is also approved for moderate-to-severe asthma in patients 6 years of age and older, and for chronic rhinosinusitis with nasal polyps in patients 12 years of age and older whose disease is not adequately controlled [5].
What are the risks associated with Dupixent?
Common side effects of Dupixent include injection site reactions, conjunctivitis, oral herpes, and other forms of dermatitis [5]. Serious allergic reactions can occur, and patients should seek medical attention if they experience symptoms such as rash, swelling, or difficulty breathing [5].
How much does Dupixent cost?
The cost of Dupixent can be substantial and varies depending on insurance coverage and patient assistance programs. As of recent data, the list price for a month's supply can be several thousand dollars [6].
How does Dupixent compare to other treatments?
Dupixent represents a significant advancement for patients with type 2 inflammatory diseases, offering a targeted approach to reduce inflammation [5]. Its efficacy and safety profile are distinct from older systemic immunosuppressants and topical treatments [5]. Comparisons with other biologics targeting different inflammatory pathways are ongoing as research evolves.
What are the latest clinical trial results for Dupixent?
Ongoing clinical trials continue to explore Dupixent's efficacy and safety in new indications and patient populations, as well as to gather long-term data. Information on the latest clinical trial results can often be found on the websites of its developers or in scientific publications [4].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.regeneron.com/
[5] https://www.dupixent.com/
[6] https://www.goodrx.com/